Cover image
Cover: Magnetic resonance imaging (MRI) of a stroke in the territory of the middle cerebral artery (MCA) in a mouse (top) and human (bottom). Images are oriented from rostral (left image) to caudal (right image). The mouse images show typical stroke propagation at 24 hours after 1 hour of middle cerebral artery occlusion (MCAO). Cortical and sub-cortical lesions can be seen, corresponding to a severe human stroke. The lower panel shows the stroke of a 65-year-old male patient in the territory of the right MCA. Mouse MRI images are courtesy of Odilo Engel (Charité, Berlin). See Clinical Puzzle by Mergenthaler and Meisel on page 718.
This issue
Other journals from The Company of Biologists
DMM and COVID-19
We are aware that the COVID-19 pandemic is having an unprecedented impact on researchers worldwide. The Editors of all The Company of Biologists’ journals have been considering ways in which we can alleviate concerns that members of our community may have around publishing activities during this time. Read about the actions we are taking at this time.
Please don’t hesitate to contact the Editorial Office if you have any questions or concerns.
The twin pillars of Disease Models & Mechanisms
In her first Editorial as Editor-in-Chief, Liz Patton sets out her vision and priorities for DMM focusing on four thematic challenges: mechanisms of disease, innovative technologies, disease progression through time and therapy.
Extended deadline - The RAS Pathway: Diseases, Therapeutics and Beyond
Our upcoming special issue is welcoming submissions until 3 May 2021. Guest-edited by Donita Brady (Perelman School of Medicine at the University of Pennsylvania, USA) and Arvin Dar (Icahn School of Medicine at Mount Sinai, USA), the issue will focus on the targeting the RAS pathway.
Find out more about the issue and how to submit your manuscript.
Perspective - Modelling the developmental origins of paediatric cancer to improve patient outcomes
James Amatruda authors our first Perspective, discussing some of the key challenges in paediatric cancer from his perspective as a physician-scientist.
A muscle growth-promoting treatment based on the attenuation of activin/myostatin signalling results in long-term testicular abnormalities
In this issue’s Editor’s choice, Ketan Patel and colleagues describe how even brief exposure to muscle-growth-promoting treatments exerts a long-term detrimental effect on the testes, and test promising therapeutics to mitigate this side-effect.